Full Press Release Details
Life Sciences to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
NEW YORK, September 8, 2023 - Tiziana Life Sciences Ltd. (Nasdaq:
TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies
via novel routes of drug delivery, today announced that the Company will virtually present and host one-on-one meetings at the H.C. Wainwright
25th Annual Global Investment Conference, being held September 11-13, 2023.
| Event: | H.C. Wainwright 25 th Annual Global Investment Conference |
| Date: | Presentation to be accessible on-demand, beginning 7:00 AM EDT, Monday, September 11 th , 2023 |
| Format: | Virtual company presentation and 1-on-1 meetings |
| Registration: | https://journey.ct.events/view/9083a450-c597-41e2-8a02-2ffe070bef75 |
About Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage
biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes
of immunotherapy. Tiziana's innovative nasal approach has the potential to provide an improvement
in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana's lead candidate, intranasal
foralumab, which is the only fully human anti-CD3 mAb, has demonstrated a favorable safety profile and clinical response in patients in
studies to date. Tiziana's technology for alternative routes of immunotherapy has been patented with several applications pending
and is expected to allow for broad pipeline applications.
For further inquiries:
Tiziana Life Sciences Ltd
Paul Spencer, Business Development and Investor
+44 (0) 207 495 2379
email: info@tizianalifesciences.com
LifeSci Advisors, LLC